Browse the evidence

There were no significant changes in peak VO2 or other cardiovascular measures with HU6 treatment.

HU6 may not improve cardiovascular function despite weight loss.

25,215 adverse event reports related to tirzepatide were identified, predominantly in the 65 to 85 age group.

Healthcare providers should be aware of the high volume of AE reports in older adults using tirzepatide.

Novel adverse event signals include thyroid mass, medullary thyroid carcinoma, and conditions affecting the reproductive system and breast.

Clinicians should be vigilant for these specific adverse events in patients treated with tirzepatide.

The direct to consumer genetic testing market is estimated to total about $100 million in 2017.

Practitioners should be aware of the significant financial scale of the DTC genetic testing market.

2/3 of American adults and 1/6 of American children and adolescents are considered either overweight or obese.

Health professionals should be aware of the high prevalence of overweight and obesity in the population.

Innovative engineering technologies are needed to address problems in energy balance, intake, and expenditure associated with obesity.

There is a need for collaboration between engineers and health scientists to develop effective obesity interventions.

There is limited clinical trial data on the safety and efficacy of anti-obesity medications for patients with heart failure.

Practitioners should be aware of the limited evidence when considering anti-obesity medications for heart failure patients.

The prevalence of obesity has increased markedly in recent decades, constituting major medical and socioeconomic problems worldwide.

Awareness of the obesity epidemic is crucial for public health initiatives.

There are currently no clear guidelines for the prehabilitation of obese patients with dysglycemia undergoing bariatric surgery.

Healthcare providers should recognize the need for developing guidelines for prehabilitation in this patient population.

Current community-based lifestyle modification programs are unlikely to be effective in preventing diabetes.

Reassess the design and implementation of lifestyle modification programs for diabetes prevention.

Measured daily average CO2 production rates were not significantly different between the diets.

Dietary composition may not significantly affect metabolic rates as measured by CO2 production.

Challenges in ensuring safety, tolerability, and equitable access are critical barriers to advancing anti-obesity pharmacotherapy.

Address these barriers to improve obesity treatment outcomes.

The Maycoba Project focuses on the etiology of type 2 diabetes (T2D) and obesity in Mexican Pima Indians.

Practitioners may gain insights into T2D and obesity in this specific population.

Surveys conducted in 1995 and 2010 included medical history, biochemical, and anthropometric measurements.

Practitioners can utilize this data collection approach for similar studies.

Obesity is projected to affect 3.8 billion people worldwide by 2050.

Practitioners should be aware of the increasing obesity trend and its implications for health.

The global prevalence of obesity has risen sharply during the past half-century, reaching pandemic proportions.

Clinicians should be aware of the increasing obesity rates as a public health concern.

Conventional drug therapies explored in OSA have generally produced disappointing results.

Practitioners should be aware that current drug therapies for OSA may not be effective.

Cardiovascular-Renal-Hepatic-Metabolic diseases are increasing globally, posing significant challenges for patient care and clinical research.

Healthcare providers should be aware of the increasing prevalence of these diseases.

There were no effects on diet quality for the 'tax' and 'healthier substitute offers.'

Strategies such as taxing unhealthy foods and offering healthier substitutes may not improve diet quality.

All-cause mortality was not different in patients allocated to sibutramine or placebo.

Weight loss interventions may not significantly affect overall mortality in this population.

Procter & Gamble spent an estimated $500 million over 30 years to bring olestra to market.

Understanding the financial commitment can inform discussions on corporate influence in food marketing.

P&G conducted a comprehensive campaign to obtain support from FDA and Congress for olestra.

Awareness of corporate lobbying efforts can inform public health policy discussions.

There is a general recommendation against the use of non–FDA‐approved compounded incretin analogs.

Clinicians should be cautious and consider FDA approval status when prescribing incretin analogs.

Approximately 10% of obesity-related glomerulopathy (ORG) patients progress to end stage renal disease 6.2 years after diagnosis.

Healthcare providers should monitor ORG patients closely for progression to end stage renal disease.